Compare Biogen Inc (BIIB) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Star Bulk Carriers Corp — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Star Bulk Carriers Corp trades at $27.91 (market cap $3.09B). The key difference: Biogen Inc is far larger — about 9.8× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.79% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SBLK | |
|---|---|---|
Market Cap | $30.13B | $3.09B |
Sector | Health | Industrials |
52-Week High | $216.63 | $29.15 |
52-Week Low | $128.93 | $16.79 |
Enterprise Value | $37.20B | $3.77B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Star Bulk Carriers (SBLK) trades at $27.81, down 2.15% on the day, but maintains a bullish technical outlook with strong support at $27. Fundamentally, the company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Revenue growth accelerated to $1.2 billion in 2026, driving a net margin of 23.86%. Recent news highlights the termination of a vessel sale agreement with Diana Shipping, though operations remain unaffected.
The outlook for SBLK is positive, supported by strong profitability, a healthy balance sheet with a debt-to-asset ratio of 27.84%, and a shareholder-friendly dividend policy. Risks include exposure to volatile dry bulk shipping rates and competitive pressures. Analyst consensus is bullish with 58.34% buy ratings, indicating confidence in continued earnings momentum and valuation appeal at a P/E of 10.85.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
